Human Phenotype Ontology 
Grandparent Node:
expand
Abnormal circulating hormone concentration (HP:0003117)help
Parent Node:
expand
Abnormal circulating androgen level (HP:0030347)help
..Starting node
..expand
Increased circulating androgen concentration (HP:0030348)help
Term ID: 30348
Name: Increased circulating androgen concentration
Synonym: Hyperandrogenemia; Increased circulating androgen level
Definition: An elevation of the blood concentration of an androgen, that is, of a steroid hormone that controls development and maintenance of masculine characteristics. The androgens include testosterone and Dehydroepiandrosterone.
Comments:
Reference: HP:0030348
Genes and Diseases:
 
       Child Nodes:
........expandIncreased serum androstenedione (HP:0025380) help
........expandIncreased serum testosterone level (HP:0030088) help

 Sister Nodes: 
..expandAbnormal circulating dehydroepiandrosterone concentration (HP:0500022) help
..expandAbnormal circulating testosterone concentration (HP:0030087) help
..expandDecreased circulating androgen concentration (HP:0030349) help
InputHPO IDHPO termDistanceGeneGene id entrezHGNC IDDiseaseIdDiseaseNameFrequencyOnsetHGMD variantsClinVar variants
 
HPO disease - gene - phenotype typical associations:
 
HPO disease - gene - phenotype less frequent non-typical associations:
HP:0030348HP:0030348Increased circulating androgen concentration0ALG6 CL E G H2992923157ORPHA:79320ALG6-CDGHP:0040284 - Very rare66
HP:0030348HP:0030348Increased circulating androgen concentration0ALMS1 CL E G H7840428ORPHA:64Alström syndromeHP:0040283 - Occasional404
HP:0030348HP:0030348Increased circulating androgen concentration0AR CL E G H367644ORPHA:99429Complete androgen insensitivity syndrome125
HP:0030348HP:0030348Increased circulating androgen concentration0AR CL E G H367644ORPHA:90797Partial androgen insensitivity syndrome125
HP:0030348HP:0030348Increased circulating androgen concentration0CDKN2A CL E G H10291787ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent289
HP:0030348HP:0030348Increased circulating androgen concentration0CLN3 CL E G H12012074ORPHA:228346CLN3 disease216
HP:0030348HP:0030348Increased circulating androgen concentration0CTNNB1 CL E G H14992514ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent88
HP:0030348HP:0030348Increased circulating androgen concentration0CYP11B1 CL E G H15842591OMIM:202010Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency112
HP:0030348HP:0030348Increased circulating androgen concentration0CYP11B1 CL E G H15842591ORPHA:90795Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiencyHP:0040281 - Very frequent112
HP:0030348HP:0030348Increased circulating androgen concentration0FSHR CL E G H24923969ORPHA:64739Ovarian hyperstimulation syndrome50
HP:0030348HP:0030348Increased circulating androgen concentration0GNAS CL E G H27784392ORPHA:562McCune-Albright syndrome101
HP:0030348HP:0030348Increased circulating androgen concentration0HSD3B2 CL E G H32845218ORPHA:90791Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiency34
HP:0030348HP:0030348Increased circulating androgen concentration0INSR CL E G H36436091ORPHA:769Rabson-Mendenhall syndromeHP:0040282 - Frequent229
HP:0030348HP:0030348Increased circulating androgen concentration0NR2F2 CL E G H70267976OMIM:61890146,XX SEX REVERSAL 5; SRXX513
HP:0030348HP:0030348Increased circulating androgen concentration0POLR3A CL E G H1112830074ORPHA:3455Wiedemann-Rautenstrauch syndrome138
HP:0030348HP:0030348Increased circulating androgen concentration0POLR3A CL E G H1112830074OMIM:264090Wiedemann-Rautenstrauch syndrome138
HP:0030348HP:0030348Increased circulating androgen concentration0PRKAR1A CL E G H55739388ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent134
HP:0030348HP:0030348Increased circulating androgen concentration0PRKAR1A CL E G H55739388OMIM:610489Pigmented nodular adrenocortical disease, primary, 1134
HP:0030348HP:0030348Increased circulating androgen concentration0TERT CL E G H701511730ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent238
HP:0030348HP:0030348Increased circulating androgen concentration0TP53 CL E G H715711998ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent911
HP:0030348HP:0030348Increased circulating androgen concentration0WNT4 CL E G H5436112783ORPHA:247768Müllerian aplasia and hyperandrogenism4
HP:0030348HP:0030348Increased circulating androgen concentration0ZNRF3 CL E G H8413318126ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent
HP:0030348HP:0030088Increased serum testosterone level1AR CL E G H367644ORPHA:99429Complete androgen insensitivity syndromeHP:0040281 - Very frequent125
HP:0030348HP:0030088Increased serum testosterone level1AR CL E G H367644ORPHA:90797Partial androgen insensitivity syndromeHP:0040281 - Very frequent125
HP:0030348HP:0025380Increased circulating androstenedione concentration1CDKN2A CL E G H10291787ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent289
HP:0030348HP:0025380Increased circulating androstenedione concentration1CTNNB1 CL E G H14992514ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent88
HP:0030348HP:0025380Increased circulating androstenedione concentration1CYP11B1 CL E G H15842591OMIM:202010Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency112
HP:0030348HP:0030088Increased serum testosterone level1CYP11B1 CL E G H15842591OMIM:202010Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency112
HP:0030348HP:0030088Increased serum testosterone level1CYP11B1 CL E G H15842591ORPHA:90795Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiencyHP:0040283 - Occasional112
HP:0030348HP:0025380Increased circulating androstenedione concentration1CYP11B1 CL E G H15842591ORPHA:90795Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiencyHP:0040281 - Very frequent112
HP:0030348HP:0030088Increased serum testosterone level1FSHR CL E G H24923969ORPHA:64739Ovarian hyperstimulation syndromeHP:0040281 - Very frequent50
HP:0030348HP:0030088Increased serum testosterone level1GNAS CL E G H27784392ORPHA:562McCune-Albright syndromeHP:0040282 - Frequent101
HP:0030348HP:0030088Increased serum testosterone level1HSD3B2 CL E G H32845218ORPHA:90791Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiencyHP:0040282 - Frequent34
HP:0030348HP:0025380Increased circulating androstenedione concentration1HSD3B2 CL E G H32845218ORPHA:90791Congenital adrenal hyperplasia due to 3-beta-hydroxysteroid dehydrogenase deficiencyHP:0040282 - Frequent34
HP:0030348HP:0030088Increased serum testosterone level1INSR CL E G H36436091ORPHA:769Rabson-Mendenhall syndromeHP:0040282 - Frequent229
HP:0030348HP:0030088Increased serum testosterone level1NR2F2 CL E G H70267976OMIM:61890146,XX SEX REVERSAL 5; SRXX513
HP:0030348HP:0030088Increased serum testosterone level1POLR3A CL E G H1112830074OMIM:264090Wiedemann-Rautenstrauch syndrome.138
HP:0030348HP:0030088Increased serum testosterone level1POLR3A CL E G H1112830074ORPHA:3455Wiedemann-Rautenstrauch syndromeHP:0040284 - Very rare138
HP:0030348HP:0025380Increased circulating androstenedione concentration1PRKAR1A CL E G H55739388ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent134
HP:0030348HP:0030088Increased serum testosterone level1PRKAR1A CL E G H55739388OMIM:610489Pigmented nodular adrenocortical disease, primary, 1134
HP:0030348HP:0025380Increased circulating androstenedione concentration1TERT CL E G H701511730ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent238
HP:0030348HP:0025380Increased circulating androstenedione concentration1TP53 CL E G H715711998ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent911
HP:0030348HP:0030088Increased serum testosterone level1WNT4 CL E G H5436112783ORPHA:247768Müllerian aplasia and hyperandrogenismHP:0040281 - Very frequent4
HP:0030348HP:0025380Increased circulating androstenedione concentration1ZNRF3 CL E G H8413318126ORPHA:1501Adrenocortical carcinomaHP:0040282 - Frequent


Genes (18) :ALG6 ALMS1 AR CDKN2A CLN3 CTNNB1 CYP11B1 FSHR GNAS HSD3B2 INSR NR2F2 POLR3A PRKAR1A TERT TP53 WNT4 ZNRF3

Diseases (17) :ORPHA:79320 ORPHA:64 ORPHA:99429 ORPHA:90797 ORPHA:1501 ORPHA:228346 OMIM:202010 ORPHA:90795 ORPHA:64739 ORPHA:562 ORPHA:90791 ORPHA:769 OMIM:618901 ORPHA:3455 OMIM:264090 OMIM:610489 ORPHA:247768
 

Human Phenotype Ontology(HPO) is developed by the Human Phenotype Ontology Consortium. The version used here is December 15 2022 release.